A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 163
Last updated 2017-09-05
Summary
Evaluate the safety and tolerability of VX-659 in healthy subjects
Conditions
Interventions
- DRUG
-
VX-659
- DRUG
-
Tezacaftor
- DRUG
-
Ivacaftor
- DRUG
-
VX-659 Matching Placebo
- DRUG
-
Triple Combination (TC) Matching Placebos
Sponsors & Collaborators
-
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2017-08-31
- Completion
- 2017-08-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT02508207 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03447249 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03768089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
NCT02730208 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
NCT02516410 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT02070744 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525444 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
NCT03633526 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
NCT02951195 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
NCT03486236 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
NCT05437120 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03460990 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
NCT02412111 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
NCT02565914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
NCT03068312 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
NCT02953314 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
NCT03691779 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
NCT02347657 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT02392234 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
NCT05111145 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
NCT01531673 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2